Shopping Cart
Remove All
Your shopping cart is currently empty
Onartuzumab (Synonyms: RG-3638, PRO-14396, MetMAb)
Catalog No. T76780 Copy Product Info
🥰Excellent
Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.Onartuzumab has antitumor activity with inhibitory effects on HGF binding, receptor phosphorylation, and signal transduction.
Onartuzumab
Copy Product Info🥰Excellent
Catalog No. T76780
Synonyms RG-3638, PRO-14396, MetMAb
Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.Onartuzumab has antitumor activity with inhibitory effects on HGF binding, receptor phosphorylation, and signal transduction.
Cas No. 1133766-06-9
Customer service consultation
| Pack Size | Price | USA Stock | Global Stock | Quantity |
|---|---|---|---|---|
| 1 mg | $243 | In Stock | In Stock | |
| 5 mg | $787 | - | In Stock | |
| 10 mg | $1,230 | - | In Stock | |
| 25 mg | $2,380 | - | In Stock | |
| 50 mg | $3,230 | - | In Stock |
For In stock only · Estimated delivery: USA Stock (1-2 days) Global Stock (5-7 days)
Add to Cart
Add to Quotation
For research use only—not for human use. No sales to individuals. Use as intended only.
Batch Information
Select Batch
Purity:97.3% (SDS-PAGE); 97.6% (SEC-HPLC)
Appearance:Liquid
Color:Transparent
Contact us for more batch information
Resource Download
Product Introduction
Bioactivity
Related Conjugates and Formulations
Antigen Details
Chemical Properties
Antibody Information
Storage & Solubility Information
| Description | Onartuzumab (MetMAb) is a humanized anti-tyrosine kinase c-MET monovalent monoclonal antibody.Onartuzumab has antitumor activity with inhibitory effects on HGF binding, receptor phosphorylation, and signal transduction. |
| Targets&IC50 | c-Met:1.8 n M |
| In vitro | Onartuzumab acts specifically by blocking the binding of the HGF α-chain (but not β-chain) to MET[1]. With an inhibitory concentration (IC50) of 1.8 nM, Onartuzumab effectively blocks HGF binding to human c-Met. This inhibition results in the prevention of c-Met auto-phosphorylation and subsequent cell proliferation in numerous cancer cell lines[2]. |
| In vivo | Administered twice a week for two months at a dose of 30 mg/kg via intraperitoneal injection, Onartuzumab suppresses tumor growth[3]. |
| Synonyms | RG-3638, PRO-14396, MetMAb |
| Reactivity | Human |
| Verified Activity | Immobilized Human HGFR/c-Met Protein (His) (TMPY-01296) at 1 μg/mL (100 μL/well) can bind Onartuzumab. The EC50 is 9.65 ng/mL.  |
| Application | Functional assay |
| Antibody Type | Monoclonal |
| Formulation | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| Endotoxin | <1.0 EU/mg |
| Conjucates | Unconjugated |
| Gene ID | |
| Uniprot ID | |
| Target | HGFR/c-Met |
| Molecular Weight | 146.99 kDa |
| Cas No. | 1133766-06-9 |
| Isotype | IgG1 |
| Storage | Store at low temperature | Shipping with blue ice/Shipping at ambient temperature. |
Calculator
Preview
Related Tags: buy Onartuzumab | purchase Onartuzumab | Onartuzumab cost | order Onartuzumab | Onartuzumab chemical structure | Onartuzumab in vivo | Onartuzumab in vitro | Onartuzumab molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.